clinical trial · NCT03905707
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
Short Bowel Syndromeglepaglutide
brief summary
The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS). Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
started
May 7, 2019
primary completion
Apr 30, 2026
completion
Apr 30, 2026
last updated
Sep 8, 2026
detailed description
A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients with Short Bowel Syndrome (SBS)
official title
A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients With Short Bowel Syndrome (SBS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol